Treatment of Metastatic Pancreatic Cancer with ECOG Performance Status 0–1 and Serum Bilirubin Below 1.5× ULN
Clinical Scenario
This protocol applies to patients with metastatic pancreatic cancer who have a good functional status — ECOG performance status 0 or 1 — and a serum bilirubin level below 1.5 times the upper limit of normal.
Treatment Approach
When no standard chemotherapy regimen can be recommended in this setting, supportive care is the appropriate treatment choice. For patients with preserved performance status, the full protocol identifies a preferred first option — see the structured regimens for the complete approach.
References
DOI: 10.1016/j.annonc.2023.08.009
In patients with ECOG PS 0-1 and bilirubin level <1.5 times the ULN, two regimens should be considered: FOLFIRINOX [I, A; ESMO-MCBS v1.1 score: 5] or GN [I, A; ESMO-MCBS v1.1 score: 3].
In such cases, no standard regimen can be recommended and BSC is the appropriate treatment choice.
In patients with a good PS, inclusion in a clinical trial is the first option when available.
View source ↗